Cassava Announces Closure of U.S. Department of Justice Investigation
AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the U.S. Department of Justice Fraud Section (DOJ) has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.). That indictment was dismissed with prejudice by DOJ on October 23, 2025.
As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission (SEC) of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC’s allegations.
The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.
“We welcome the resolution of these investigations and remain dedicated to maintaining the trust of all our stakeholders. As we move forward, we will continue to focus our efforts on developing a novel treatment for TSC-related epilepsy,” said Richard J. Barry, President and Chief Executive Officer of Cassava.
About Cassava Sciences, Inc.
Cassava Sciences, Inc. (NASDAQ: SAVA), is a biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and potentially other indications.
For more information, please visit: https://www.CassavaSciences.com
Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Direxion Daily Semiconductor Bear ETF gains 13.63%, faces $42.90 upper Bollinger band
As AI momentum begins to recede, Buffett-style "boring investments" quietly make a comeback
After years of AI and momentum trading dominance, the "quality factor" investment strategy is making a strong comeback. Driven by the repricing of interest rate expectations and slowing profit growth, capital is shifting focus from chasing growth to emphasizing profit quality and robust balance sheets. The long quality, short momentum strategy has surged 55% so far this year. The quality factor is negatively correlated with AI; amid crowded momentum positions, Warren Buffett's philosophy of steadfastly holding high-quality assets is once again gaining recognition on Wall Street.
Siebert Financial analyst targets $175,000 bitcoin price, cites ETFs and stablecoin growth
Quarterly Revenue Hits 16.8 Billion for IPO Push—Can Anthropic’s Profits Support a $2 Trillion Valuation?
Anthropic disclosed Q3 revenue of $16.8 billion and achieved adjusted profitability. Compared to OpenAI's expectations and projected massive losses in 2025, the analysis covers Anthropic's enterprise growth logic, competitive landscape, and the rationality of its $2 trillion valuation.
Crypto prices
More
